U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum

More than 80 global executives attended the China Development Forum as Beijing signals easier foreign access and larger purchases of healthcare and digital tech; China reported a record trade surplus in 2025 and a US-China trade truce temporarily cut effective tariffs to <50% for a year. Apple noted China accounted for nearly 18% of revenue in the December quarter and said iPhone sales in the first nine weeks were up 23% YoY after the iPhone 17 launch, while Apple claims >90% of its China production runs on clean energy. Eli Lilly plans to invest $3.0B in China over the next decade (China ~3% of its revenue) and saw its Mounjaro drug added to China’s reimbursement list; Volkswagen is launching 20 new models after an 8% drop in China passenger car sales last year.

Analysis

Senior-level engagement from multinationals signals Beijing is once again prioritizing an investment narrative over confrontation; the market reaction will be sector- and supplier-specific rather than a uniform re-risking into China. Expect accelerated onshore capex and automation projects to raise demand for capital goods, industrial software and clean-energy contractors — benefiting suppliers with local scale and certified ESG credentials while intensifying bargaining leverage over foreign HQs on margins and pricing.

A measured reopening-driven uptick in discretionary spending creates a window for brand owners and payment networks to grow high-margin revenue, but that upside is lumpy and conditional on policy clarity (reimbursement, service market access, app fee rules). For autos, a surge in model introductions and incentives will compress OEM margins and kB share growth even as component demand rises; parts and software suppliers will see volume gains but also price pressure and consolidation risk.

Key tail risks are geopolitical shocks (trade truce lapse, export curbs on strategic inputs) and domestic policy reversals that can flip flows within weeks but whose economic effects play out over quarters. Practically, catalytic moves to watch are policy announcements on services-market access and rare-earth export rules (near-term, 0–3 months) and concrete procurement or reimbursement frameworks for foreign healthcare/digital products (mid-term, 3–12 months).

Key Decisions for Investors

• AAPL — Tactical long via 3–6 month call spread entered within 2 weeks: buy a near-term call and sell a higher strike to fund premium. Size 3–5% of equity tech sleeve. R/R: defined upside (target 10–20% relative to current spot) with limited premium at risk; hedge catalyst risk (trade truce lapse) by buying a small protective put.
• TPR — Buy shares or 9–12 month calls to capture luxury/consumer rebound in China and regional tourist demand. Entry on any 3–7% pullback in underlying; target 25–40% upside over 6–12 months, downside protected by optionality (max premium loss). Key stop: persistent RMB weakness or renewed policy tightening.
• MA — Buy 12–18 month LEAPS calls as a convex play on cross-border and digital payment volume normalization, funded by selling short-dated OTM calls to improve carry. Expect multi-quarter payoff if services access commitments materialize; downside limited to premium outlay but regulatory or local-rail competition could delay upside.
• Portfolio hedge — Buy 3–6 month protection on China/EM equity exposure (index puts or inexpensive put spreads) sized to offset 30–50% of China-exposed positions. Rationale: political/geopolitical shocks can compress multiple rapidly within weeks; cost of hedge justified by asymmetric tail risk.